Develop the science base to inform the regulation of tobacco products and the marketing of these products;
Develop empirically-based models of tobacco use behavior that integrate the effects of pro-tobacco marketing and anti-tobacco messages on perceptions of the risks and benefits of tobacco use, and how these perceptions affect decisions to start, continue, stop, relapse, switch tobacco products;
Evaluate the rapid changes in health risks due to tobacco use and secondhand smoke exposure as shown through cardiovascular and pulmonary disease to support the development of mechanistically-based biomarkers;
Implement an education and training program for postdoctoral fellows, and collaborate with other TCORS;
Attract new faculty investigators to develop research that will support tobacco regulatory science, and implement a developmental pilot program that will allow TCORS investigators and fellows to pursue new opportunities that arise from their projects.
The UCSF TCORS also has two developmental projects - one on risk perceptions of smoking by older Americans, and another to develop better animal models of the cardiovascular effects of secondhand smoke and exposure to other tobacco products, said Glantz. It also expands UCSF-s postdoctoral training program in tobacco control.
-We-ve identified issues in the way the FDA has done cost-benefit analysis of major tobacco regulations, most notably warning labels on cigarette packages,- Glantz said. -In particular, the FDA underestimated the immediate benefits of smoking prevention and cessation, and based its behavioral assumptions on outmoded ideas.
-By combining cutting edge economic research with modern behavior studies, and studies of the immediate effects of smoke exposure on the cardiovascular and pulmonary systems, we hope to help the FDA develop cost-benefit models that are more realistic than current models which will better support sensible regulation.-
At UCSF, the center-s individual project primary investigators are Wendy Max, PhD, professor of health economics at the UCSF School of Nursing and director of the UCSF Institute for Health & Aging; Bonnie L. Halpern-Felsher, PhD, professor in the department of pediatrics; Margaret Walsh, EdD, professor of preventive and restorative sciences; Carolyn S. Calfee, MD, associate professor of medicine and anesthesia; Peter Ganz, MD, UCSF professor of medicine and chief of cardiology at the UCSF-affiliated San Francisco General Hospital and Trauma Center; Janine Cataldo, RN, PhD, assistant professor at the School of Nursing; and Matthew L. Springer, PhD, associate professor medicine. Other leading participants are Karen Butter, MA, university librarian and assistant vice chancellor; and Peyton Jacob, PhD, research chemist in the department of psychiatry. Co-investigators are Neal Benowitz, MD, professor of medicine and bioengineering & therapeutic sciences and chief of the division of clinical pharmacology at SFGH; and Pamela M. Ling, MD, MPH, associate professor of medicine and associate director of the UCSF Center for Tobacco Control and Research and education.
Source: University of California - San Francisco